Back HIV/AIDS HIV/AIDS Topics HIV Prevention CROI 2014: Long-acting GSK744 Protects Monkeys against HIV-like Virus [VIDEO]

CROI 2014: Long-acting GSK744 Protects Monkeys against HIV-like Virus [VIDEO]

alt

A long-acting injectable formulation of the next-generation integrase inhibitor GSK1265744 protected monkeys from infection via vaginal or anal exposure to a hybrid human-simian virus, according to 2 studies presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston. These promising findings suggest this may be a future approach to pre-exposure prophylaxis (PrEP).

[Chasity Andrews and J. Gerardo Garcia-Lerma,CROI press conference, March 4, 2014]

3/5/14

Sources

CD Andrews, W Spreen, YL Yueh, et al. Correlating GSK1265744 Plasma Levels To Prevention of Rectal SHIV Transmission in Macaques. 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014). Boston, March 3-6. Abstract 39.

J Radzio, W Spreen, YL Yueh, JG Garcia-Lerma, et al. Monthly GSK744 Long-Acting Injections Protect Macaques Against Repeated Vaginal SHIV Exposures. 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014). Boston, March 3-6. Abstract 40LB.

Press conference. 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014). Boston. March 4, 2014.